Show simple item record

LEADER-4: blood pressure control in patients with type 2 diabetes and high cardiovascular risk: baseline data from the LEADER randomized trial

dc.contributor.authorMasmiquel, Luis
dc.contributor.authorPetrie, John R.
dc.contributor.authorMarso, Steven P.
dc.contributor.authorBain, Stephen C.
dc.contributor.authorFranek, Edward
dc.contributor.authorJacob, Stephan
dc.contributor.authorLeiter, Lawrence A.
dc.contributor.authorHaluzik, Martin
dc.contributor.authorOmar, Mohamed
dc.contributor.authorShestakova, Marina
dc.contributor.authorVan Gaal, Luc
dc.contributor.authorMann, Johannes F.
dc.contributor.authorBaeres, Florian M. M.
dc.contributor.authorZinman, Bernard
dc.contributor.authorPoulter, Neil R.
dc.contributor.authorSatman, Ilhan
dc.date.accessioned2021-03-04T10:18:27Z
dc.date.available2021-03-04T10:18:27Z
dc.date.issued2016
dc.identifier.citationPetrie J. R. , Marso S. P. , Bain S. C. , Franek E., Jacob S., Masmiquel L., Leiter L. A. , Haluzik M., Satman I., Omar M., et al., "LEADER-4: blood pressure control in patients with type 2 diabetes and high cardiovascular risk: baseline data from the LEADER randomized trial", JOURNAL OF HYPERTENSION, cilt.34, sa.6, ss.1140-1150, 2016
dc.identifier.issn0263-6352
dc.identifier.othervv_1032021
dc.identifier.otherav_6c803432-1707-43c9-ad32-783055fa6b67
dc.identifier.urihttp://hdl.handle.net/20.500.12627/74999
dc.identifier.urihttps://doi.org/10.1097/hjh.0000000000000890
dc.description.abstractObjective: As glucagon-like peptide-1 receptor agonists lower blood pressure (BP) in type 2 diabetes mellitus (T2DM), we examined BP control in relation to targets set by international bodies prior to randomization in the Liraglutide Effect and Action in Diabetes: Evaluation of cardiovascular outcome Results (LEADER) trial.
dc.language.isoeng
dc.subjectPERİFERAL VASKÜLER HASTALIĞI
dc.subjectSağlık Bilimleri
dc.subjectTıp
dc.subjectKlinik Tıp (MED)
dc.subjectKlinik Tıp
dc.titleLEADER-4: blood pressure control in patients with type 2 diabetes and high cardiovascular risk: baseline data from the LEADER randomized trial
dc.typeMakale
dc.relation.journalJOURNAL OF HYPERTENSION
dc.contributor.departmentUniversity Of Glasgow , ,
dc.identifier.volume34
dc.identifier.issue6
dc.identifier.startpage1140
dc.identifier.endpage1150
dc.contributor.firstauthorID233220


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record